Luca Issi joined RBC Capital Market in 2020, and is covering Biotech. Prior to RBC, he was an investor at Bain Capital Life Sciences, where he led private and public investments across biopharmaceutical, medical device, specialty pharma and tools & diagnostics.
Join Barron’s Live weekdays at noon, for timely and actionable insights tied to the coronavirus crisis. Dial-in to connect with top experts and our editors covering the outbreak, to hear the impact on markets, the economy, companies, real estate, and more.Session topics subject to change pending breaking news. Barron's senior managing editor Lauren R. Rublin, reporter Al Root and a special guest discuss the outlook for the aerospace industry.
By RBC Capital Markets With Arjun Goyal, Co-Founder and Managing Director of Vida Ventures Key Points Vida Ventures is at the forefront of investing in biotech innovation, and they are focused on key modalities like gene therapy, oncology and rare diseases. A major investment opportunity in oncology is the trend
Safety scares, including deaths of several young study subjects, have set back efforts to bring more gene therapies to market, clouding one of biotech’s most promising technologies and hottest sectors.
The next generation of companies that can deliver new gene therapy formats that will be safer, less toxic, and easier to manufacture.